To The Moon

$Sarepta Therapeutics(SRPT)$ 🅱️ U͎ L͎ L͎ I͎ S͎ H͎ 🚨🧬💥 Sarepta: The Genomic Equation Wall Street Forgot to Solve 💥🧬🚨 $SRPT | 04Apr25, 🇳🇿NZ Time Current Price: $59.08 Mean Target: $168.91 | Implied Upside: +186.01% Support: $57.20 | Resistance: $75.00 The chart behaviour mirrors historical recovery cycles preceding Sarepta’s 2019 breakout, with compression zones once again converging toward expansion. Sarepta Therapeutics stands poised at the intersection of scientific inflection, commercial maturity, and market underappreciation. The narrative has shifted from speculative to operational, from hope to hard numbers. Yet pricing remains trapped in a dislocation that may not persist much longer. ELEVIDYS has emerged not only as a breakthrough in treatment, but as a masterclass in execution. Sarepta secured the broadest FDA label available, fulfilling the full ambitions of Project Moonshot. Since launch, the gene therapy has generated over $1 billion in sales, with Q4 2024 contributing $384 million, representing a 112 percent surge from the prior quarter. This was not momentum, it was validation. The company’s fiscal evolution is equally striking. Sarepta exited 2024 profitably, both on a net basis and in terms of free cash flow. Net product revenue reached $1.8 billion, up 56 percent year over year, and 2025 guidance projects between $2.9 and $3.1 billion, growth of over 70 percent. These figures are underpinned by strong reserves, including $1.5 billion in cash and access to an unused $600 million revolving credit facility. By 2030, Sarepta forecasts $13 billion in cumulative free cash flow and $16 billion in operating income. This is not a trajectory, it’s a blueprint for long term capital efficiency. Strategically, the partnership with Arrowhead Pharmaceuticals has positioned Sarepta as a dual platform innovator. With gene therapy and siRNA now integrated, the pipeline is no longer linear, it is multidimensional, with the potential to address a spectrum of rare diseases at scale. Despite these structural strengths, the stock trades at just $59.08. The disconnect between current price and institutional consensus is striking. The average analyst price target stands at $168.91, with projections ranging from $75.00 to $215.00. TD Cowen reaffirmed its Buy rating with a target of $203, stating, “We view Sarepta as one of the most undervalued companies in gene therapy, with ELEVIDYS already proving to be a paradigm shift in rare disease commercialisation.” Needham maintained their Buy rating with a target of $183, noting, “Sarepta is now demonstrating operational scalability without needing to rely on future catalysts, the story is already unfolding.” FactSet aggregates a consensus target of $165.36, reinforcing that the current valuation is disconnected from operational reality. Analyst sentiment remains resolute: 🟢 Buy: 18 🟡 Hold: 4 🔴 Sell: 0 Meanwhile, technical and capital flow indicators are beginning to align. The current VWAP cluster ranges tightly between $58.57 and $59.08, acting as structural support. ARBR readings show BR at 139.86 versus AR at 127.16, clear evidence of institutional absorption. MACD signals reveal DIF rising at 0.1003, with DEA at 0.1315 and histogram pressure softening, suggesting fading downside momentum. Bid ask tightness (59.02, 59.11) and volume at 2.26M with $132.1M in turnover suggest renewed positioning. While price remains below the previous close of $62.47, today’s high of $60.15 signals reversion is already being tested intraday. On the earnings front, Q1 estimates are unequivocally strong. Revenue is forecast at $684.7 million, up 65.60 percent, with EPS expected at $0.87, up 135.14 percent. Sarepta is demonstrating not only top line expansion but strong operating leverage. Peer analysis further confirms the valuation gap. Vertex and BioMarin trade closer to their targets, despite narrower pipelines. Sarepta offers broader future optionality and deeper near term catalysts, yet remains mispriced. The chart confirms what fundamentals imply. The structural arc now visible on Sarepta’s long term pattern resembles the pre-2019 compression and reacceleration phase. The technical rhythm, institutional conviction, and commercial validation are now fully aligned. This may not simply be a rebound. This is the early phase of a monstrous bounce embedded in both the behavioural symmetry of the price and the empirical evolution of the business. Hey Tiger Traders, is Sarepta’s recovery already coded into its past, and are we now watching its valuation renaissance unfold? 📢 Please Like, Repost, and Follow me for sharp setups, stock trends, and actionable insights 🚀📈 I’m all about spotting the next movers and sharing strategies that deliver results! Let’s trade smarter and grow together! 🍀🍀🍀 Happy trading ahead! Cheers, BC 📈🚀🍀🍀🍀